Organization
Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA
2 abstracts
Abstract
Development and validation of an AI-derived digital pathology-based biomarker to predict benefit of long-term androgen deprivation therapy with radiotherapy in men with localized high-risk prostate cancer across multiple phase III NRG/RTOG trials.Org: Artera, Vancouver, BC, Canada, Department of Pathology, University of California San Francisco, San Francisco, CA, Tulane University, New Orleans, LA, University of California, San Francisco, San Francisco, CA, Case Western Reserve University, Cleveland, OH,
Abstract
A clinical-genetic (CG) circulating tumor DNA (ctDNA)-based prognostic model for predicting overall survival (OS) in men with metastatic castrate-resistant prostate cancer (mCRPC) treated with potent androgen receptor inhibition (Alliance).Org: Department of Biostatistics and Bioinformatics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University School of Medicine, Duke University Medical Center, Duke University Department of Biostatistics and Bioinformatics,